| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8221113 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 8 Pages |
Abstract
Taken together, chemoradiation therapy combined with cetuximab is safe, feasible, and offers excellent survival rates. KRAS mutation status was not a predictive factor. Importantly, lack of improvement in pCR rate did not translate to poor survival in our clinical trial.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Emmanouil MD, DPhil, Lena MD, Christian MD, Thilo MD, Peter MD, Tillman MD, Kathrin MD, Julia MD, Franz PhD, Rolf MD, Josef MD, Tim PhD, Dirk MD, B. Michael MD, Claus MD, Torsten MD,